Novo Announces Collaboration With Anthropic To Accelerate AI‑Driven Drug Discovery

Novo announced a collaboration with Anthropic to integrate the latter’s large‑language‑model AI into Novo’s early‑stage drug discovery workflow, aiming to speed target identification, generate novel compound ideas, and lower overall research expenses.

Anthropic will supply its newest generative AI platform, which has been trained on millions of biomedical publications and molecular datasets, enabling it to propose chemical structures, assess predicted activity, and prioritize candidates for laboratory testing, the partners said.

AI‑Discovered Drugs currently occupy a full pipeline of clinical‑trial programs in 2026, spanning oncology, infectious disease, and rare disorders, illustrating that AI‑generated candidates are moving beyond the lab and providing a proof‑of‑concept base for the Novo‑Anthropic effort.

Vision Lifesciences reported on June 27, 2026 that AI tools are reshaping drug discovery pipelines, citing faster hit identification and reduced synthesis cycles, and highlighted that Novo’s partnership aligns with industry momentum toward AI‑driven research.